FIELD: biotechnology.
SUBSTANCE: invention relates to improved methods of conjugation of agent with thiol group in protein comprising at least one disulfide bond and at least one trisulfide bond.
EFFECT: methods enable to produce antibody-drug conjugates which contain practically no impurities which are produced in the presence of reactive sulfide components in production processes.
113 cl, 4 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MATERIALS AND METHODS ASSOCIATED WITH LINKERS FOR USE IN DRUG AND PROTEIN CONJUGATES | 2015 |
|
RU2737553C2 |
| METHOD FOR DOUBLE CONJUGATION FOR OBTAINING ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2771310C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| ANTI-CD71 CONJUGATES ACTIVATED ANTIBODY-DRUG AND THEIR APPLICATION METHODS | 2018 |
|
RU2771292C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| LINKER FOR ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2792201C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| METHOD FOR CONJUGATION OF A POLYPEPTIDE | 2015 |
|
RU2715905C2 |
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
